Furthermore, clinical trials are ongoing or planned to assess the benefits of GM-CSF-targeted therapy for COVID-19 or CAR-T- or GvHD-related cytokine release syndrome (CRS; [3, 54, 55]). Here, CSF2 is linked to COVID-19.